secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001140361-25-035634
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports positive pivotal study results for zilganersen in Alexander disease; NDA planned Q1 2026
--------------------------------------------------------------------------------

- Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.
- No approved disease-modifying treatments for Alexander disease; first investigational drug to show positive impact.
- Safety profile favorable: most adverse events mild/moderate; SAEs numerically lower in zilganersen arm.
- NDA submission to FDA targeted for Q1 2026; evaluating U.S. Expanded Access Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125035634/0001140361-25-035634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125035634/ef20055880_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-035634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer